Buffer exchange path influences the stability and viscosity upon storage of a high concentration protein

Graphical abstract Figure. No caption available. ABSTRACT High concentration protein solutions are generally produced by spin column concentration (SCC) during early development and by tangential flow filtration (TFF) during later stages, when greater quantities of protein become available. This is based on the assumption that the protein generated by the SCC process would be fairly similar to the TFF process material. In this study, we report the case of high concentration solutions of an Fc fusion protein produced by the two processes using the same upstream drug substance (DS) with very different storage stability. The TFF and SCC batches were characterized for aggregation, viscosity, and hydrodynamic radius before and after storage at different temperatures (5°C, 25 °C, and 40 °C). Aggregation and viscosity of the solutions processed by TFF were higher than those processed by SCC upon storage at 25 °C and 40 °C for three months. Differential scanning fluorimetry (DSF) revealed differences in initial protein conformation. Upon exposure to shear stress, protein solutions showed conformational instability and increased aggregation upon storage at 35 °C. In addition, protein solution showed higher aggregation upon shearing under mixed (downstream purification process and final formulation) buffer conditions – which are more likely to be encountered during the TFF, but not SCC, process. These results were further confirmed in an independent experiment by Fourier transform‐infrared (FT‐IR) spectroscopy and aggregation analysis. Taken together, these data indicate that shearing the protein in intermediate, unstable buffer conditions can lead to conformational perturbation during TFF processing, which led to higher rate of aggregation and viscosity upon storage. This study highlights the importance of testing shear stress sensitivity in the transitional buffer states of the TFF process early in development to de‐risk process related product instability.

[1]  Li Li,et al.  Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development , 2016, mAbs.

[2]  John F. Carpenter,et al.  Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation , 2003, Pharmaceutical Research.

[3]  H. Bunjes,et al.  Comparison of different protein concentration techniques within preformulation development. , 2011, International journal of pharmaceutics.

[4]  Steven J Shire,et al.  Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. , 2005, Journal of pharmaceutical sciences.

[5]  Nripen Singh,et al.  Effect of channel-induced shear on biologics during ultrafiltration/diafiltration (UF/DF) , 2016 .

[6]  Eva Rosenberg,et al.  Ultrafiltration concentration of monoclonal antibody solutions: Development of an optimized method minimizing aggregation , 2009 .

[7]  Chung C. Hsu,et al.  Protein denaturation by combined effect of shear and air-liquid interface. , 1997, Biotechnology and bioengineering.

[8]  G. Senisterra,et al.  High throughput methods of assessing protein stability and aggregation. , 2009, Molecular bioSystems.

[9]  C. Pace,et al.  Forces contributing to the conformational stability of proteins , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  H. Mach,et al.  High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective. , 2012, Therapeutic delivery.

[11]  Linda O Narhi,et al.  High throughput thermostability screening of monoclonal antibody formulations. , 2010, Journal of pharmaceutical sciences.

[12]  M. Benoit,et al.  Biophysical approaches promote advances in the understanding of von Willebrand factor processing and function. , 2017, Advances in biological regulation.

[13]  Prasad Sarangapani,et al.  Protein aggregation, particle formation, characterization & rheology , 2014 .

[14]  Steven J Shire,et al.  Challenges in the development of high protein concentration formulations. , 2004, Journal of pharmaceutical sciences.

[15]  P. Minghetti,et al.  Injectability Evaluation: An Open Issue , 2011, AAPS PharmSciTech.

[16]  G. Abraham,et al.  Reversible self-association of a human myeloma protein. Thermodynamics and relevance to viscosity effects and solubility. , 1984, Biochemistry.

[17]  S. Hagen,et al.  Do protein molecules unfold in a simple shear flow? , 2006, Biophysical journal.

[18]  Anuj Chaudhri,et al.  Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations. , 2015, Molecular pharmaceutics.

[19]  I. Roy,et al.  Protein aggregation. , 2017, International journal of biological macromolecules.

[20]  Chung C. Hsu,et al.  Effect of high shear on proteins , 2000, Biotechnology and bioengineering.

[21]  Alexandra Lavoisier,et al.  Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection , 2014, mAbs.